Scholarlink

Background <p>Our phase Ib neoadjuvant trial demonstrated that oncolytic virus (OV) combined with PD-1 blockade achieved a 77.8% pathological response rate and 81.5% 2-year relapse-free survival in patients with acral melanoma. Here, we report the sustained clinical efficacy from an extended 5-year follow-up and characterize the molecular determinants of resistance to inform a biomarker-driven combinatorial strategy.</p> Methods <p>Thirty patients with resectable acral melanoma were enrolled and followed for 5-year survival. Pre- and post-treatment tumor tissues with matched blood samples were analyzed using integrated WES, WTS, TBS, and Olink proteomics. These multi-omic profiles were leveraged to delineate resistance mechanisms in non-responders, which were subsequently validated in murine melanoma models exploring STING agonist-based combination therapy.</p> Results <p>At a median follow-up of 62.4 months, the 5-year relapse-free and overall survival rates were 70.7% (95% CI, 53.7–93.0%) and 80.0% (95% CI, 66.9–95.7%), respectively. Integrated multi-omics analyses revealed that non-responders, in contrast to responders, exhibited a failure in therapeutic remodeling of the tumor microenvironment. Specifically, non-responders were characterized by baseline innate immune suppression linked to STING pathway downregulation; low baseline <i>STING</i> expression significantly correlated with diminished immune infiltration and inferior clinical outcomes. In murine melanoma models, pharmacological activation of the STING pathway restored innate immune signaling and synergistically augmented the antitumor efficacy of OV plus PD-1 regimen.</p> Conclusions <p>These data establish the durable long-term clinical benefits of neoadjuvant OV plus PD-1 blockade in acral melanoma. Our findings identify STING dysfunction as a key mediator of therapeutic resistance, providing a rational for integrating STING agonists to optimize the clinical efficacy of this combinatorial approach.</p> <p><i>Trial registration</i> Retrospectively registered: NCT04197882, 2019-12-13.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-term survival benefit of neoadjuvant oncolytic virus plus PD-1 blockade in acral melanoma: implications of STING in resistance and potential therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月1日

查看全文
  • Qian Zhao,
  • Yu Du,
  • Lifeng Li,
  • Lili Mao,
  • Xuan Wang,
  • Zelong Xu,
  • Jiayong Liu,
  • Chuanliang Cui,
  • Zhihong Chi,
  • Xuan Gao,
  • Kaihua Liu,
  • Shuang Chang,
  • Yan Kong,
  • Xinan Sheng,
  • Xuefeng Xia,
  • Jun Guo,
  • Jie Dai,
  • Lu Si

摘要

Background

Our phase Ib neoadjuvant trial demonstrated that oncolytic virus (OV) combined with PD-1 blockade achieved a 77.8% pathological response rate and 81.5% 2-year relapse-free survival in patients with acral melanoma. Here, we report the sustained clinical efficacy from an extended 5-year follow-up and characterize the molecular determinants of resistance to inform a biomarker-driven combinatorial strategy.

Methods

Thirty patients with resectable acral melanoma were enrolled and followed for 5-year survival. Pre- and post-treatment tumor tissues with matched blood samples were analyzed using integrated WES, WTS, TBS, and Olink proteomics. These multi-omic profiles were leveraged to delineate resistance mechanisms in non-responders, which were subsequently validated in murine melanoma models exploring STING agonist-based combination therapy.

Results

At a median follow-up of 62.4 months, the 5-year relapse-free and overall survival rates were 70.7% (95% CI, 53.7–93.0%) and 80.0% (95% CI, 66.9–95.7%), respectively. Integrated multi-omics analyses revealed that non-responders, in contrast to responders, exhibited a failure in therapeutic remodeling of the tumor microenvironment. Specifically, non-responders were characterized by baseline innate immune suppression linked to STING pathway downregulation; low baseline STING expression significantly correlated with diminished immune infiltration and inferior clinical outcomes. In murine melanoma models, pharmacological activation of the STING pathway restored innate immune signaling and synergistically augmented the antitumor efficacy of OV plus PD-1 regimen.

Conclusions

These data establish the durable long-term clinical benefits of neoadjuvant OV plus PD-1 blockade in acral melanoma. Our findings identify STING dysfunction as a key mediator of therapeutic resistance, providing a rational for integrating STING agonists to optimize the clinical efficacy of this combinatorial approach.

Trial registration Retrospectively registered: NCT04197882, 2019-12-13.

Graphical Abstract